New classes of drugs like Wegovy (a GLP-1 agonist similar to Ozempic) and Zepbound could certainly help the millions of obese Americans and people around the globe struggling to shed weight.

By now, these are household names: Mounjaro. Wegovy. Zepbound… and yes, Ozempic. A Kaiser Family Foundation poll found that one in 8 American adults reported trying a GLP-1 medication.

while Zepbound received FDA approval for weight loss in November 2023. The table below introduces six stocks and one ETF that stand to benefit from Ozempic's popularity. The table is followed by a ...

A shortage of weight-loss drugs such as the newly released Ozempic rival Zepbound, is forcing desperate customers to drive as much as five hours to find a pharmacy that has the pricey meds in stock.

Amongst these, three drugs are making headlines time and again: Ozempic (which never really left the spotlight), and the comparatively newer players, Zepbound and Mounjaro. But can these ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth ... of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe proposed by ...